Crown Bioscience, Inc. is a platform technology company providing drug discovery and development services in the areas of Oncology and Inflammation.
CrownBio helps biopharmaceutical companies solve some of today's most pressing challenges in oncology with an offering of end-to-end preclinical solutions, a unique collection of ready-to-run, well-validated in vitro, in vivo, and ex vivo models, and cutting-edge technologies.
Our Translational Platforms bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates.
CrownBio provides preclinical immunotherapy research platforms to support the successful transition of immunotherapeutics from the lab into the clinic including models for the evaluation of CAR-T therapies, syngeneics, and humanized models.
Our team of experts worldwide, comprising highly trained PhD and MS scientists, provides services to Pharmaceutical, Biotechnology companies, and Biomedical Research Institutes around the world.
TCG Lifesciences Pvt. Limited (formerly "Chembiotek Research International") is a leading global Contract Researchand Manufacturing Services (CRAMS) company in the area of drug discovery and development. We started our operations in 2001 in Kolkata, India and currently have our presence in the United States, Europe, and Japan.
We have a strong talent pool of 800+ qualified and trained scientists (including 150+ PhDs), drawn from the best domestic and international institutes and industry. Our services span chemistry, in vitro and in vivo pharmacology, analytical development and validation, and specialty chemicals. We offer specific/functional solutions to integrated projects across multiple therapeutic areas with specific focus on Inflammation & Pain, Infectious Diseases, Central Nervous System and Oncology. Our research infrastructure includes world-class chemistry and biology laboratories, animal facility, electrophysiology laboratory, BSL 2 laboratory, and cGMP facilities at our R&D centers.
• Scaffolds & Building Blocks
• Library Synthesis
• Parallel Synthesis
• Medicinal Chemistry Singletons
• Solid Phase and Solution Phase Peptide Synthesis
• In vitro Pharmacology
• Pharmacokinetics and Pharmacodynamics (PK/PD)
• In vitro Toxicology
• In vivo Pharmacology
Fully Integrated Services
• Medicinal Chemistry Design
• Lead Generation
• Lead Optimization
• Preclinical Candidate Selection
• Rapid Scale-Up and cGMP Kilo Labs
• Route Evaluation
• Hazard Assessment & Reaction Calorimetry
• Process R&D
• Clinical Trial Materials Preparation
• cGMP Analytical Lab
• Methods Development & Validation
• Forced Degradation Studies
• Impurity Profile Determination
• Impurity Isolation and Characterization
• Preparative Chromatography (chiral, SFC, and HPLC)
• Reference Standards Management
• ICH Stability Studies
AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation. We develop our product candidates to address emerging biological targets using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, or SHM, and replicates this natural process of antibody generation in vitro. Our strategy is to advance the development and commercialization of our proprietary product candidates, and for certain programs, establish partnerships with leading biopharmaceutical companies where we retain certain development and commercialization rights in the United States.
Our wholly-owned product pipeline includes etokimab (ANB020) and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. We are advancing etokimab, an antibody that inhibits the activity of interleukin-33, for the treatment of moderate-to-severe adult atopic dermatitis, severe adult eosinophilic asthma, and adult chronic rhinosinusitis with nasal polyps (CRSwNP).
In addition, we are developing our ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP).
Our company is led by a strong management team with a proven track record of successfully growing biotechnology companies with deep experience in antibody discovery and development, collaborations, operations and corporate finance.
Additionally, multiple AnaptysBio-generated antibodies have entered the clinic under our immuno-oncology-focused collaboration with TESARO and inflammation-focused collaboration with Celgene.
Invivotek LLC, a member of Genesis Biotechnology Group® (GBG) is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013.
Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.